Serum osteoprotegerin and renal osteodystrophy | Zendy

G Coen | Zendy; P. Ballanti | Zendy; Alessandro Balducci | Zendy; Santo Calabria | Zendy; Maria Stephanie Fischer | Zendy; Ljiljana Janković | Zendy; Micaela Manni | Zendy; Massimo Morosetti | Zendy; Eleonora Moscaritolo | Zendy; Daniela Sardella | Zendy; E. Bonucci | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum osteoprotegerin and renal osteodystrophy

Author(s) -

G Coen,

P. Ballanti,

Alessandro Balducci,

Santo Calabria,

Maria Stephanie Fischer,

Ljiljana Janković,

Micaela Manni,

Massimo Morosetti,

Eleonora Moscaritolo,

Daniela Sardella,

E. Bonucci

Publication year - 2002

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/17.2.233

Subject(s) - renal osteodystrophy , osteoprotegerin , medicine , bone remodeling , endocrinology , parathyroid hormone , bone resorption , bone disease , pathogenesis , cytokine , osteoporosis , kidney disease , receptor , calcium , activator (genetics)

Numerous growth factors and cytokines are known to modulate bone turnover. An important, recently discovered complex involved in osteoclastogenesis is the osteoprotegerin/osteoprotegerin-ligand (OPG/OPGL) cytokine complex, which is produced by osteoblasts. Many factors, including parathyroid hormone (PTH), appear to affect bone turnover through this pathway. In this disorder, the role of the OPG/OPGL system in the pathogenesis of renal osteodystrophy, a disease with either low or high bone turnover, has not been investigated so far.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research